Stock Events

Stock Events

Genfit 

€13.60
109
-€0.18-1.31% 06:05 Today

Statistics

Day High
13.6
Day Low
13.6
52W High
14.86
52W Low
3.01
Volume
-
Avg. Volume
-
Mkt Cap
680.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29SepExpected
Q1 2024
Q2 2024
Q1 2025
Q2 2025
Q1 2026
Next
-0.51
0
0.51
1.02
Expected EPS
-0.019665816375999998
Actual EPS
N/A

Financials

-131.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
65.43MRevenue
-85.97MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XUP.F. It's not an investment recommendation.
TotalEnergies
21
TTE.PA
Air Liquide
18
AI.PA
Engie
18
ENGI.PA
Axa
14
CS.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.5B
Madrigal Pharmaceuticals is focused on developing therapies for NASH, directly competing with Genfit's NASH programs.
Viking Therapeutics
VKTX
Mkt Cap4.07B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor to Genfit.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences has a strong pipeline in liver diseases, including NASH treatments, positioning it as a competitor to Genfit.
Agios Pharmaceuticals
AGIO
Mkt Cap1.98B
Agios Pharmaceuticals, though primarily focused on cancer and rare genetic diseases, has interests in metabolic disorders, potentially overlapping with Genfit's work.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.34M
Galmed Pharmaceuticals is developing therapies for liver diseases, including NASH, competing in the same space as Genfit.
Axsome Therapeutics
AXSM
Mkt Cap10.83B
Axsome Therapeutics, primarily focused on CNS disorders, has a broader portfolio that could intersect with metabolic diseases treatment, indirectly competing with Genfit.

About

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.
Show more...
CEO
Pascal Prigent
Employees
161
Country
France
ISIN
FR0004163111
WKN
000A0LGJ2

Listings

MU
DE
XUP.MU
STU
DE
XUP.STU
F
DE
XUP.F
XETRA
DE
XUP.XETRA

0 Comments

Share your thoughts

FAQ

What is Genfit stock price today?▼
The current price of XUP.F is €13.60 EUR — it has decreased by -1.31% in the past 24 hours. Watch Genfit stock price performance more closely on the chart.
What is Genfit stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Genfit stocks are traded under the ticker XUP.F.
Is Genfit stock price growing?▼
XUP.F stock has fallen by -4.9% compared to the previous week, the month change is a -0.15% fall, over the last year Genfit has showed a +307.92% increase.
What is Genfit market cap?▼
Today Genfit has the market capitalization of 680.49M
When is the next Genfit earnings date?▼
Genfit is going to release the next earnings report on September 29, 2026.
What is Genfit revenue for the last year?▼
Genfit revenue for the last year amounts to 65.43M EUR.
What is Genfit net income for the last year?▼
XUP.F net income for the last year is -85.97M EUR.
How many employees does Genfit have?▼
As of September 07, 2026, the company has 161 employees.
In which sector is Genfit located?▼
Genfit operates in the Health & Wellness sector.
When did Genfit complete a stock split?▼
Genfit has not had any recent stock splits.
Where is Genfit headquartered?▼
Genfit is headquartered in Loos, France.